

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/582,621
Filing Date	June 12, 2006
First Named Inventor	Pallaoro et al.
Group Art Unit	-- 1633
Examiner Name	-- Marv.
Attorney Docket Number	ITR0053YP



Sheet 1 of 4

U.S. PATENT DOCUMENTS

[illegible]

duplicate references

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Maria Marvich/	Date Considered	10/25/2008
--------------------	-----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IOS Form" (IOS Folder), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/582,621
Filing Date	June 12, 2006
First Named Inventor	Pallaoro et al.
Group Art Unit	--
Examiner Name	--
Attorney Docket Number	ITR0053YP

Sheet	2	of	4
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/M.M./	AA	Goodwin et al., Molecular Pharmacology, Vol. 56 (1999), pp. 1329-1339, "The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 ..."
/M.M./	AB	Xing et al., J. Receptor & Signal Transduction Research, Vol. 20 (2000), pp. 189-210, "A fluorescent reporter assay for the detection of ligands acting through G1 protein-coupled receptors"
	AC	Kramer et al., Trends in Endocrinol. & Metab., Vol. 12 (2001), pp. 294-300, " Histone deacetylase as a therapeutic target"
	AD	Colletti et al., Bioorg. & Med. Chem. Letters, Vol. 11 (2001), pp. 113-117, "Broad spectrum antiprotozoal agents that inhibit histone deacetylase: ..."
	AE	Archer et al., Curr. Opin. in Genetics & Develop., Vol. 9 (1999), p. 171-174, "Histone acetylation and cancer"
	AF	Colletti et al., Bioorg. & Med. Chem. Letters, Vol. 11 (2001), pp. 107-111, " Broad spectrum antiprotozoal agents that inhibit histone deacetylase: ..."
	AG	Sowa et al., Biochem. & Biophys. Res. Comm., Vol. 241 (1997), pp. 142-150, "Histone deacetylase inhibitor activates the WAF1/Cip1 gene ..."
	AH	Galameau et al., Nature Biotech., Vol. 20 (2002), pp. 819-822, "Beta-lactamase protein fragment complementation assays in vivo and in vitro ..."
	AI	Egawa et al., Biol. Pharm. Bull., Vol. 21 (1998), pp. 999-904, "Identification of active substances from Streptomyces culture ..."
/M.M./	AJ	Hustert et al., Drug Metab. & Disposition, Vol. 29 (2001), pp. 1454-1459, "Natural protein variants of pregnane X receptor with altered transactivation ..."
	AK	Zlokarnik et al., Science, Vol. 279 (1998), p. 84-88, "Quantitation of transcription and clonal selection of single living cells ..."
	AL	Vigushin et al., Anti-Cancer Drugs, Vol. 13 (2002), pp. 1-13, "Histone deacetylase inhibitors in cancer treatment"
	AM	Nare et al., Anal. Biochem., Vol. 267 (1999), pp. 390-396, " Development of a scintillation proximity assay for histone deacetylase using a biotinylated peptide ..."
	AN	Huang et al., Oncogene, Vol. 19 (2000), pp. 5712-5719, "Activation of the p21 WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor ..."
	AO	Grozinger et al., Chem. & Biol., Vol. 9 (2002), pp. 3-16, "Deacetylase Enzymes. Biological functions and the use of small-molecule inhibitors"

Examiner Signature	/Maria Marvich/	Date Considered	10/25/2008
--------------------	-----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/582,621
Filing Date	June 12, 2006
First Named Inventor	Pallaoro et al.
Group Art Unit	--
Examiner Name	--
Attorney Docket Number	1TR0053YP

Sheet	3	of	4
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/M.M./	AP	Goodwin et al., Molec. Pharmacol., Vol. 62 (2002), pp. 359-365, "Transcriptional regulation of the human CYP3A4 gene by the constitutive ..."
	AQ	Marks et al., Nature Rev., Vol. 1 (2001), pp. 194-202, "Histone deacetylases and cancer: causes and therapies"
	AR	Meinke et al., Curr. Med. Chem., Vol. 8 (2001), pp. 211-235, "Histone deacetylase: A target for antiproliferative and antiparasitic agents"
/M.M./	AS	Raucy et al., J. Pharmacol. & Exper. Therapeutics, Vol. 303 (2002), pp. 412-423, "A cell-based reporter gene assay for determining induction of CYP3A4 ..."
	AT	Meinke et al., J. Med. Chem., Vol. 43 (2000), pp. 4919-4922, "Synthesis of apicidin-derived quinoline derivatives: parasite-selective histone deacetylase ..."
	AU	Sambouret et al., J. Biol. Chem., Vol. 274 (1999), pp. 34940-34947, "Histone deacetylase inhibition selectively alters the activity and expression of cell cycle ..."
	AV	Cress et al., J. Cell. Physiol., Vol. 184 (2000), pp. 1-16, "Histone deacetylases, transcriptional control, and cancer"
/M.M./	AW	Nakano et al., J. Biol. Chem., Vol. 272 (1997), pp. 22199-22206, "Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites ..."
	AX	Han et al., J. Biol. Chem., Vol. 276 (2001), pp. 42084-42090, "Activation of p21-WAF1/Cip1 transcription through Sp1 sites ..."
/M.M./	AY	Drocourt et al., J. Biol. Chem., Vol. 277 (2002), pp. 25125-25132, "Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D ..."
	AZ	Sowa et al., Cancer Res., Vol. 50 (1990), pp. 4266-4270, "Sp7, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene ..."
	BA	Ju et al., Cancer Res., Vol. 63 (2003), pp. 2891-2897, "Histone deacetylase inhibitors activate p21-WAF1 expression via ATM"
	BB	Furumai et al., Cancer Res., Vol. 62 (2002), pp. 4910-4921, "FK228 (depsipeptide) as a natural product that inhibits Class I ..."
	BC	Zlokovic et al., Science, Vol. 279 (1998), pp. 84-88, "Quantitation of transcription and clonal selection of single living cells ..."
	BD	Taunton et al., Science, Vol. 272 (1996), pp. 408-411, "A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p"

Examiner Signature	/Maria Marvich/	Date Considered	10/25/2008
--------------------	-----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/582,621
Filing Date	June 12, 2006
First Named Inventor	Pallaoro et al.
Group Art Unit	--
Examiner Name	--
Attorney Docket Number	ITR0053YP

Sheet	4	of	4
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	*Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	BE	Rishon et al., PNAS, Vol. 97 (2000), pp. 10014-10019, "Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylation"
	BF	Mcinke et al., Tetra. Letters, Vol. 41 (2000), pp. 7831-7835, "Synthesis of side chain modified apicidin derivatives: potent mechanism-based histone ..."
	BG	Colletti et al., Tetra. Letters, Vol. 41 (2000), pp. 7837-7841, "Design and synthesis of histone deacetylase inhibitors: the development of apicidin ..."
	BH	Colletti et al., Tetra. Letters, Vol. 41 (2000), pp. 7825-7829, "Tryptophan-replacement and indole-modified apicidins: synthesis of potent and selective ..."
	BI	Archer et al., PNAS, Vol. 95 (1998), pp. 6791-6796, "p21WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells"
	BJ	Xiao et al., J. Cell. Biochem., Vol. 73 (1999), pp. 291-302, "Both Sp1 and Sp3 are responsible for p21 waf1 promoter activity induced by histone ..."
	BK	Genbank No. U24170, "Human p21 (WAF1) gene, partial promoter sequence", submitted April 5, 1995
	BL	Genbank No. AF497972, "Homo sapiens cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) gene, complete cds", submitted April 2, 2002
	BM	Genbank No. Z85996, "Human DNA sequence from clone RP3-431A14 on chromosome 6p21, complete sequence, submitted January 16, 2007
	BN	Perez et al., Proc. of the Am. Assoc. for Cancer Res., 93rd Annual Meeting, March 2002, Vol. 13, Abstract No. 3671, "Discovery and SAR of NVP-LAQ824, a novel histone deacetylase inhibitor with in vitro and in vivo antitumor activity"
		duplicate refer

duplicate references

Examiner Signature	/Maria Mayvich/	Date Considered	10/25/2008
-----------------------	-----------------	--------------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006